Last reviewed · How we verify
fluticasone propionate nasal spray + loratadine
fluticasone propionate nasal spray + loratadine is a Corticosteroid + antihistamine combination Small molecule drug developed by MEDA Pharma GmbH & Co. KG. It is currently FDA-approved for Allergic rhinitis (seasonal and perennial).
This combination reduces allergic rhinitis symptoms by suppressing nasal inflammation via corticosteroid action and blocking histamine-mediated allergic responses via H1-receptor antagonism.
This combination reduces allergic rhinitis symptoms by suppressing nasal inflammation via corticosteroid action and blocking histamine-mediated allergic responses via H1-receptor antagonism. Used for Allergic rhinitis (seasonal and perennial).
At a glance
| Generic name | fluticasone propionate nasal spray + loratadine |
|---|---|
| Sponsor | MEDA Pharma GmbH & Co. KG |
| Drug class | Corticosteroid + antihistamine combination |
| Target | Glucocorticoid receptor (fluticasone); H1-histamine receptor (loratadine) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a topical corticosteroid that inhibits inflammatory mediator release and reduces nasal mucosal inflammation. Loratadine is a selective H1-receptor antagonist that blocks histamine-induced allergic symptoms systemically. Together, they provide both local anti-inflammatory and systemic antihistamine effects for comprehensive allergy symptom control.
Approved indications
- Allergic rhinitis (seasonal and perennial)
Common side effects
- Headache
- Epistaxis (nasal bleeding)
- Nasal irritation
- Somnolence
- Dry mouth
Key clinical trials
- MP-AzeFlu Allergen Chamber - Onset of Action Study (PHASE4)
- Personalized Treatment Algorithms for Difficult-to-treat Asthma (PHASE2)
- A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure (PHASE4)
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fluticasone propionate nasal spray + loratadine CI brief — competitive landscape report
- fluticasone propionate nasal spray + loratadine updates RSS · CI watch RSS
- MEDA Pharma GmbH & Co. KG portfolio CI
Frequently asked questions about fluticasone propionate nasal spray + loratadine
What is fluticasone propionate nasal spray + loratadine?
How does fluticasone propionate nasal spray + loratadine work?
What is fluticasone propionate nasal spray + loratadine used for?
Who makes fluticasone propionate nasal spray + loratadine?
What drug class is fluticasone propionate nasal spray + loratadine in?
What development phase is fluticasone propionate nasal spray + loratadine in?
What are the side effects of fluticasone propionate nasal spray + loratadine?
What does fluticasone propionate nasal spray + loratadine target?
Related
- Drug class: All Corticosteroid + antihistamine combination drugs
- Target: All drugs targeting Glucocorticoid receptor (fluticasone); H1-histamine receptor (loratadine)
- Manufacturer: MEDA Pharma GmbH & Co. KG — full pipeline
- Therapeutic area: All drugs in Allergy/Immunology
- Indication: Drugs for Allergic rhinitis (seasonal and perennial)
- Compare: fluticasone propionate nasal spray + loratadine vs similar drugs
- Pricing: fluticasone propionate nasal spray + loratadine cost, discount & access